retatrutide gip glp-1 glucagon receptor agonist GLP1-GIP co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica TrimRX | GLP-1 vs GIP:

A licensed provider reviews your information and decides whether a microdose program is appropriate for you and what that looks like

All patients were properly diagnosed by tilt test before inclusion

Common and Rare Adverse Effects Injection site reactions represent the most common side effects, including redness and swelling (mild, transient), bruising, mild burning or cramping reported by some users, and local irritation typically resolving within hours to days

In light of emerging clinical scenarios such as adverse effects, patient preference, cost pressures or formulary decisions some healthcare professionals may consider switching a patient from tirzepatide to semaglutide